Literature DB >> 36000874

Lacticaseibacillus rhamnosus Lcr35 Stimulates Epithelial Vaginal Defenses upon Gardnerella vaginalis Infection.

Sylvie Miquel1, Julien Verlaguet1, Sophie Garcin2, Thomas Bertran2, Bertrand Evrard2,3, Christiane Forestier1, Marjolaine Vareille-Delarbre1.   

Abstract

Dysbiosis of the vaginal microbiome as a result of overgrowth of anaerobic bacteria, such as Gardnerella vaginalis, and low levels of "healthy" lactobacilli leads to bacterial vaginosis (BV), usually associated with a low-grade inflammatory process. Despite appropriate antibiotic treatment, G. vaginalis-associated BV is characterized by significant recurrence. The use of probiotics could be an interesting alternative therapy due to their ability to rebalance vaginal microbiota. In this study, we investigated the effects of a well-characterized probiotic strain, Lacticaseibacillus rhamnosus Lcr35, on epithelial vaginal and dendritic cell (DC) immune responses after G. vaginalis infection. In an in vitro coculture model with human monocyte-derived dendritic cells and a vaginal epithelial cell (VEC) monolayer, the Lcr35 strain induced DC activation, as evidenced by the induction of maturation and synthesis of interleukin-8 (IL-8) and CCL-20 chemokines upon apical challenge of the VECs by G. vaginalis. Analysis of the vaginal epithelial response showed that the presence of Lcr35 significantly increased the production of the proinflammatory cytokines IL-8 and IL-1β and human β-defensin 2 (HBD-2), whereas the concentration of secretory leukocyte protease inhibitor (SLPI) was decreased in G. vaginalis-infected vaginal epithelial cells. Treatment with recombinant SLPI was associated with upregulation of Lcr35-stimulated IL-8 and HBD-2 production. These results suggest that inhibition of SLPI by Lcr35 in vaginal epithelial cells contributes to the host defense response against G. vaginalis infection.

Entities:  

Keywords:  Gardnerella vaginalis; Lactobacillus; antimicrobial peptides; cytokines; dendritic cells; epithelial cells; vaginosis

Mesh:

Substances:

Year:  2022        PMID: 36000874      PMCID: PMC9476927          DOI: 10.1128/iai.00309-22

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  50 in total

1.  Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen.

Authors:  P L Fidel; K A Ginsburg; J L Cutright; N A Wolf; D Leaman; K Dunlap; J D Sobel
Journal:  J Infect Dis       Date:  1997-09       Impact factor: 5.226

2.  Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data.

Authors:  Jenifer E Allsworth; Jeffrey F Peipert
Journal:  Obstet Gynecol       Date:  2007-01       Impact factor: 7.661

3.  Vaginal Immunity in Bacterial Vaginosis.

Authors:  Sabina Cauci
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725

4.  Atopobium vaginae triggers an innate immune response in an in vitro model of bacterial vaginosis.

Authors:  Erika K Libby; Kristen E Pascal; Eli Mordechai; Martin E Adelson; Jason P Trama
Journal:  Microbes Infect       Date:  2008-01-12       Impact factor: 2.700

5.  Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination.

Authors:  Clifford C Taggart; Catherine M Greene; Noel G McElvaney; Shane O'Neill
Journal:  J Biol Chem       Date:  2002-06-25       Impact factor: 5.157

6.  Probiotic lactobacillus and estrogen effects on vaginal epithelial gene expression responses to Candida albicans.

Authors:  R Doug Wagner; Shemedia J Johnson
Journal:  J Biomed Sci       Date:  2012-06-20       Impact factor: 8.410

7.  Inflammatory and antimicrobial properties differ between vaginal Lactobacillus isolates from South African women with non-optimal versus optimal microbiota.

Authors:  Monalisa T Manhanzva; Andrea G Abrahams; Hoyam Gamieldien; Remy Froissart; Heather Jaspan; Shameem Z Jaumdally; Shaun L Barnabas; Smritee Dabee; Linda G Bekker; Glenda Gray; Jo-Ann S Passmore; Lindi Masson
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

8.  Impact of vaginal douching products on vaginal Lactobacillus, Escherichia coli and epithelial immune responses.

Authors:  Helai Hesham; Alissa J Mitchell; Agnes Bergerat; Kristin Hung; Caroline M Mitchell
Journal:  Sci Rep       Date:  2021-11-29       Impact factor: 4.379

9.  Adhesion of human probiotic Lactobacillus rhamnosus to cervical and vaginal cells and interaction with vaginosis-associated pathogens.

Authors:  Sophie Coudeyras; Gwendoline Jugie; Marion Vermerie; Christiane Forestier
Journal:  Infect Dis Obstet Gynecol       Date:  2009-01-27

10.  Comparative phase I randomized open-label pilot clinical trial of Gynophilus® (Lcr regenerans®) immediate release capsules versus slow release muco-adhesive tablets.

Authors:  Caroline Dausset; Stéphane Patrier; Pawel Gajer; Claudia Thoral; Yann Lenglet; Jean-Michel Cardot; Philippe Judlin; Jacques Ravel; Adrien Nivoliez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-07-21       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.